New imaging agent could improve lymph node detection in head and neck cancer
NCT ID NCT04840472
First seen Jan 11, 2026 · Last updated Jun 07, 2026 · Updated 21 times
Summary
This early-stage study tests a radioactive imaging agent called 111In-panitumumab to see if it can safely find cancer spread to lymph nodes in people with head and neck cancer. About 28 participants will receive the agent before surgery, and researchers will compare its accuracy to the standard dye method used during surgery. The goal is to improve staging and guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.